High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia

Leukemia. 2024 Jan;38(1):202-206. doi: 10.1038/s41375-023-02075-9. Epub 2023 Nov 6.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Child
  • Cytarabine*
  • Humans
  • Induction Chemotherapy
  • Leukemia, Myeloid, Acute* / drug therapy
  • Neoplasm, Residual / drug therapy
  • Remission Induction

Substances

  • Cytarabine